COVID-19 Clinical Trials

COVID-19 Clinical Trials Market Outlook

The global COVID-19 clinical trials market is projected to reach a value of approximately USD 12.1 billion by 2035, growing at a compound annual growth rate (CAGR) of around 10.5% during the forecast period from 2025 to 2035. The surge in demand for rapid vaccine development and the necessity for effective treatment modalities in response to the COVID-19 pandemic have been pivotal in propelling this market's growth. Furthermore, the increasing collaboration between pharmaceutical companies, research institutions, and regulatory bodies has expedited clinical trial processes, allowing for the swift mobilization of resources. Additionally, advancements in clinical trial methodologies, such as adaptive trial designs and real-world evidence studies, have contributed significantly to enhancing the efficacy and speed of trials. The global urgency surrounding the pandemic has also influenced funding streams and public-private partnerships, thus creating a favorable environment for innovation in clinical research.

Growth Factor of the Market

The COVID-19 clinical trials market is experiencing significant growth due to several underlying factors driving research and development. First and foremost, the urgency created by the pandemic has prompted governments and health organizations to allocate unprecedented funding for vaccine and treatment trials. This financial influx has enabled researchers to innovate and expedite their efforts in combating the virus effectively. Another critical growth factor is the evolution of technology in clinical trial management; digital platforms and artificial intelligence are being increasingly utilized for patient recruitment, data management, and real-time monitoring of trials. Moreover, regulatory agencies are adapting their frameworks to facilitate faster approvals, which is critical when managing public health emergencies. The rise of global collaborations among biotech firms, pharmaceutical companies, and academic institutions has also been instrumental, leading to shared expertise and resources. Lastly, a growing understanding of the virus's biology and the immune response generated has enhanced the design of clinical trials targeting specific populations and variances of the virus, propelling the market further.

Key Highlights of the Market

• The COVID-19 clinical trials market is anticipated to witness a robust CAGR of 10.5% from 2025 to 2035.
• Phase III trials have dominated the market, accounting for the largest share, given the urgency to evaluate the efficacy of vaccines and treatments.
• Interventional studies are the most common study design utilized in these trials, focusing on assessing the impact of experimental drugs and therapies.
• Hospitals have emerged as the primary end-users of clinical trials, contributing substantially to patient enrollment and data collection.
• North America holds the largest share of the market due to the presence of leading pharmaceutical companies, advanced healthcare infrastructure, and significant funding for research.

By Phase

Phase I:

Phase I clinical trials primarily focus on assessing the safety of a new drug or vaccine in a small group of participants, typically ranging from 20 to 100 individuals. During this initial phase, researchers aim to determine the appropriate dosage, evaluate the pharmacokinetics, and monitor any adverse effects. The COVID-19 pandemic has accelerated the execution of Phase I trials due to the urgent need for rapid assessment of candidate vaccines and therapeutics. The emphasis on safety and tolerability has led to innovative approaches, such as the inclusion of diverse demographic groups, to ensure the findings are applicable to broader populations. The swift enrollment processes and adaptive trial designs seen in this phase have been pivotal in maintaining the momentum required during the pandemic.

Phase II:

Phase II clinical trials expand the participant group to several hundred individuals and are designed to further evaluate the efficacy of a treatment or vaccine while continuing to monitor its safety. In the context of COVID-19, these trials are crucial for establishing the initial evidence of effectiveness against the virus. Researchers assess various endpoints, including immune response and viral load reduction, while also examining longer-term safety data. The rapid development of COVID-19-specific vaccines has resulted in accelerated Phase II trials, with some candidates moving from Phase I to Phase II in record time. This fast-tracking is essential in addressing the urgent public health crisis posed by the pandemic.

Phase III:

Phase III trials are critical as they involve thousands of participants and are designed to confirm the efficacy and monitor the adverse effects of a treatment or vaccine across diverse populations. For COVID-19, these trials have been groundbreaking, as they provide the data necessary for regulatory approvals. The global urgency to develop effective vaccines has led to unprecedented collaboration between pharmaceutical companies and governments, resulting in accelerated data collection and analysis. The sheer scale of Phase III trials for COVID-19 candidates has allowed for comprehensive evaluations of safety and efficacy, providing crucial insights that inform public health decisions and vaccination strategies worldwide.

Phase IV:

Phase IV clinical trials, also known as post-marketing studies, are conducted after a treatment or vaccine has received regulatory approval. These trials serve to gather further information about the drug's effect in various populations and to monitor long-term effectiveness and safety. In the context of COVID-19, Phase IV trials are essential for understanding the real-world impact of vaccines and treatments as they are administered to the general population. This phase allows researchers to identify any rare or long-term side effects that may not have been observed in earlier phases. Continuous monitoring during Phase IV is vital for maintaining public trust in COVID-19 vaccines and treatments, thereby ensuring high compliance and uptake rates among the population.

By Study Design

Interventional Studies:

Interventional studies are a predominant study design in COVID-19 clinical trials, involving the active intervention of investigators to evaluate the effects of a treatment or vaccine on health outcomes. These trials are designed to assess the efficacy, safety, and optimal usage of new therapies targeting COVID-19. By randomly assigning participants to receive either the intervention or a control, researchers can draw robust conclusions about the effectiveness of the treatment. The urgency of the pandemic has amplified the need for interventional studies, leading to rapid enrollment and deployment of various promising drug candidates and vaccines. These studies have contributed significantly to our understanding of acceptable treatments and preventive measures against COVID-19.

Observational Studies:

Observational studies play a critical role in the COVID-19 clinical trials landscape, as they help to gather real-world data on the disease's impact, treatment effectiveness, and patient outcomes. Unlike interventional studies, researchers do not assign participants to a specific treatment; instead, they observe and analyze existing data from different patient cohorts. These studies are particularly valuable in understanding how COVID-19 affects diverse populations and in identifying potential variables that influence treatment success. Observational studies have been instrumental in the rapid generation of evidence regarding the safety of various vaccines and therapies, allowing for quicker adjustments in clinical practice guidelines in response to emerging data.

Expanded Access Studies:

Expanded access studies enable patients with serious or life-threatening conditions, such as COVID-19, to access investigational treatments outside of clinical trials when no adequate alternatives are available. This study design has become increasingly relevant during the pandemic, where patients urgently seek novel therapies while awaiting the results of formal clinical trials. Expanded access studies help gather valuable data on treatment effectiveness and patient experiences in real-world scenarios. The implementation of such studies exemplifies a compassionate approach to patient care and highlights the ethical considerations inherent in the ongoing fight against COVID-19. These studies also contribute to the understanding of treatment dynamics, offering insights that can refine future clinical trial designs.

By End User

Hospitals:

Hospitals are the primary end-users of clinical trials related to COVID-19, given their central role in patient care and clinical research. They serve as critical sites for patient recruitment, data collection, and monitoring outcomes related to various treatments and vaccines. With the ability to access a diverse patient population, hospitals can facilitate rapid enrollment in clinical trials, thus expediting the research process. Moreover, hospitals often collaborate with pharmaceutical companies and research organizations, enhancing their capacity to conduct studies effectively. The integration of COVID-19 clinical trials in hospital settings has not only supported the development of innovative treatments but has also improved patient management protocols and care strategies during the pandemic.

Clinics:

Clinics, particularly outpatient facilities and specialized care centers, are increasingly contributing to the landscape of COVID-19 clinical trials by providing access to a broader demographic of patients. These facilities can offer targeted interventions in specific populations, especially for studies focusing on long-term effects or specific comorbid conditions associated with COVID-19. The agility of clinics in enrolling participants and gathering data is vital for the success of clinical trials. Furthermore, clinics often maintain ongoing relationships with patients, which can enhance follow-up and adherence rates in studies. Their participation in COVID-19 trials strengthens the overall research network and facilitates a multifaceted approach to understanding the disease and developing effective treatments.

Research Institutes:

Research institutes play a pivotal role in the COVID-19 clinical trials market, driving innovation and scientific inquiry through rigorous research efforts. These organizations are typically at the forefront of developing new therapies and vaccines, often working in collaboration with pharmaceutical companies and healthcare organizations. Their expertise in trial design and methodologies allows for the development of robust research protocols that can efficiently evaluate the safety and efficacy of COVID-19 interventions. Moreover, research institutes often have access to cutting-edge technology and resources that facilitate advanced data analysis and interpretation. The contributions of these institutes to COVID-19 trials are essential for advancing public health and informing future research directions.

Others:

Other end-users of COVID-19 clinical trials include non-profit organizations, government health agencies, and academic institutions. These entities often engage in clinical research to address specific public health needs and contribute to the overarching goal of combating the pandemic. Non-profit organizations, for instance, may support trials through funding or advocacy, highlighting the importance of equitable access to clinical research opportunities. Government health agencies play a crucial role in overseeing the regulatory aspects of trials, ensuring ethical standards are upheld while promoting rapid response initiatives. Academic institutions contribute through their research capabilities and collaboration with industry partners. Each of these end-users plays a significant role in the broader ecosystem of COVID-19 clinical trials, fostering a comprehensive approach to addressing the challenges presented by the pandemic.

By Trial Type

Drug Trials:

Drug trials comprise a significant portion of COVID-19 clinical trials, focusing on evaluating the safety and efficacy of novel antiviral medications and other therapeutic agents. These trials are vital for identifying treatments that can alleviate the symptoms of COVID-19, reduce viral load, and improve patient outcomes. The urgency of the pandemic has spurred rapid development and testing of various drug candidates, leading to numerous trials across the globe. Drug trials are often designed to assess both short-term and long-term effects, thereby providing comprehensive data that inform clinical decisions. The race to develop effective COVID-19 therapies has necessitated innovative trial designs, allowing for flexibility in enrollment and adaptive methodologies to respond to emerging data swiftly.

Vaccine Trials:

Vaccine trials are perhaps the most visible aspect of COVID-19 clinical research, focusing on assessing the safety, efficacy, and optimal dosing of vaccine candidates. These trials have been conducted at an unprecedented pace, driven by the urgent need for effective vaccination strategies to curb the spread of the virus. The global collaboration among vaccine developers, regulatory agencies, and health organizations has facilitated rapid progress through streamlined processes and adaptive designs. Vaccine trials generally involve large participant groups and diverse demographic representation to ensure the findings are applicable across various populations. The results from these trials are critical for regulatory approvals and the rollout of vaccination programs worldwide, making them a focal point in the fight against COVID-19.

Diagnostic Trials:

Diagnostic trials focus on evaluating the effectiveness of various testing methods for COVID-19, such as PCR, antigen, and antibody tests. These trials are essential for determining the reliability, sensitivity, and specificity of diagnostic tools, which are crucial for identifying infected individuals and controlling the spread of the virus. As the pandemic has highlighted the importance of rapid and accurate testing, diagnostic trials have gained significant attention and resources. The outcomes of these trials inform public health strategies and guidelines surrounding testing protocols. Furthermore, advancements in diagnostic testing technologies enabled through these trials have led to increased accessibility and efficiency in managing COVID-19 cases.

Others:

Other trial types encompass a broad range of studies that may not fall neatly into the categories of drug, vaccine, or diagnostic trials. This includes trials focusing on the impact of social interventions, rehabilitation strategies for recovering COVID-19 patients, and studies evaluating the effects of underlying health conditions on COVID-19 outcomes. These diverse trial types are essential for understanding the multifaceted nature of the pandemic and its effects on various populations. As the global response to COVID-19 evolves, there is a growing recognition of the importance of these varied studies in informing holistic public health strategies and improving patient care. The inclusion of such trials in the clinical research landscape allows for a comprehensive understanding of the virus and its implications.

By Region

The North American region has emerged as a leader in the COVID-19 clinical trials market, primarily due to its advanced healthcare infrastructure, significant funding for research, and the presence of major pharmaceutical companies. The United States, in particular, has been at the forefront of vaccine development and clinical trials, with numerous candidates being tested across various phases. The North American market is expected to account for approximately 40% of the global market share, driven by the rapid pace of trial enrollment and favorable regulatory environments. The CAGR for this region is projected to be around 11%, reflecting the continued investment and innovation within its clinical research ecosystem.

Europe closely follows North America in the COVID-19 clinical trials landscape, with countries like Germany, the United Kingdom, and France playing pivotal roles in vaccine and drug development. The European Medicines Agency (EMA) has facilitated the approval of several vaccines and treatments, encouraging collaborative research efforts across member states. The region is expected to hold about 30% of the global market share as clinical trials continue to expand and adapt to emerging variants of the virus. The increasing collaboration between public health organizations and research institutions has created a conducive environment for clinical research. Asia Pacific is also witnessing growth in the COVID-19 trials market, with countries such as China and India ramping up their research capabilities to address the pandemic effectively.

Opportunities

The COVID-19 clinical trials market presents several lucrative opportunities for stakeholders, particularly in the realm of vaccine development and therapeutic research. The unprecedented global focus on public health has resulted in increased funding from governments, international organizations, and private investors to support research initiatives. This financial backing provides a significant opportunity for biopharmaceutical companies to innovate and accelerate the development of new treatments and vaccines. Furthermore, collaboration among various stakeholders, including academia, industry, and public health entities, fosters a conducive environment for sharing knowledge and resources, enabling faster progress in clinical trial outcomes. Companies that can harness these collaborative opportunities and leverage cutting-edge technologies, such as artificial intelligence and big data analytics, will likely position themselves favorably in the competitive landscape of COVID-19 clinical research.

Another opportunity lies in the growing emphasis on real-world evidence and adaptive trial designs. The COVID-19 pandemic has accelerated the acceptance of alternative trial methodologies that allow for more flexible and responsive clinical research. By utilizing real-world data, researchers can gain valuable insights into treatment effectiveness and patient outcomes, leading to more informed decision-making. This trend opens up avenues for innovative trial designs that can adapt to changing circumstances, such as emerging variants or shifts in public health guidance. As regulatory agencies continue to support these adaptive approaches, organizations that can swiftly implement such methodologies will enhance their ability to conduct successful and timely clinical trials.

Threats

Despite the promising outlook for the COVID-19 clinical trials market, several threats could impact its trajectory. One notable concern is the potential for vaccine hesitancy, which may arise due to misinformation and public skepticism surrounding COVID-19 vaccines and treatments. This hesitancy can hinder enrollment in clinical trials, ultimately affecting the speed and efficacy of research efforts. Additionally, the emergence of new variants of the virus poses a significant threat, as they might reduce the effectiveness of existing vaccines and treatments, necessitating further rounds of trials and evaluations. The rapidly evolving landscape requires continuous adaptation from researchers and industry stakeholders to ensure that clinical trials remain relevant and effective in addressing the challenges posed by COVID-19.

Another critical threat to the market is regulatory challenges. While regulatory agencies have expedited approval processes to facilitate COVID-19 trials, the complexity of coordinating multi-site trials and ensuring compliance with varying regulations across regions can pose significant hurdles. Furthermore, the global nature of the pandemic may lead to disparities in access to investigational therapies, raising ethical questions that researchers must navigate carefully. The potential for regulatory bottlenecks, particularly as new treatments and vaccines are developed, could slow down the pace of research. As such, effective stakeholder engagement and proactive regulatory strategies will be essential in mitigating these threats and ensuring the continued progress of COVID-19 clinical trials.

Competitor Outlook

• Pfizer Inc.
• Moderna, Inc.
• AstraZeneca PLC
• Johnson & Johnson
• BioNTech SE
• Novavax, Inc.
• Sanofi S.A.
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Roche Holding AG
• GlaxoSmithKline PLC
• Regeneron Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.

The competitive landscape of the COVID-19 clinical trials market is characterized by a diverse array of pharmaceutical companies, research institutes, and biotechnology firms vying for leadership in the development and deployment of innovative treatments and vaccines. Major players such as Pfizer and Moderna have gained significant recognition for their pioneering efforts in mRNA-based vaccine development, leading to swift regulatory approvals and widespread distribution. These companies have set benchmarks for rapid trial execution and adaptive methodologies, influencing the strategies of other firms in the market. The competition is further intensified by the global nature of the pandemic, as companies seek to establish collaborations and partnerships to enhance their research capabilities and expedite clinical trials.

In addition to established giants, several emerging biotechnology firms are making their mark by developing novel therapeutic candidates and leveraging advanced technologies. Companies like Novavax and BioNTech are notable for their innovative approaches to vaccine development, employing platforms such as recombinant protein technology and mRNA technology, respectively. These emerging players are often at the forefront of clinical research, conducting trials that explore novel mechanisms of action and efficacy against various COVID-19 variants. The dynamism in this segment reflects the urgency to address evolving public health challenges and underscores the importance of innovation in the fight against COVID-19.

Collaboration remains a significant theme within the competitive landscape, as companies increasingly engage in partnerships with governments and research institutions to pool resources and expertise. For example, AstraZeneca's collaboration with the University of Oxford has resulted in a widely distributed vaccine that is critical in controlling the pandemic. Such partnerships exemplify the collective effort to expedite clinical trials and ensure equitable access to vaccines and treatments globally. Furthermore, the competitive environment is supported by a surge in funding from both public and private sectors, allowing companies to invest in cutting-edge research and technology to improve trial designs and outcomes. The interplay of competition, collaboration, and innovation will shape the future trajectory of the COVID-19 clinical trials market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 BioNTech SE
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Moderna, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Novavax, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline PLC
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Gilead Sciences, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boehringer Ingelheim GmbH
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 COVID-19 Clinical Trials Market, By Phase
    • 6.1.1 Phase I
    • 6.1.2 Phase II
    • 6.1.3 Phase III
    • 6.1.4 Phase IV
  • 6.2 COVID-19 Clinical Trials Market, By End User
    • 6.2.1 Hospitals
    • 6.2.2 Clinics
    • 6.2.3 Research Institutes
    • 6.2.4 Others
  • 6.3 COVID-19 Clinical Trials Market, By Trial Type
    • 6.3.1 Drug Trials
    • 6.3.2 Vaccine Trials
    • 6.3.3 Diagnostic Trials
    • 6.3.4 Others
  • 6.4 COVID-19 Clinical Trials Market, By Study Design
    • 6.4.1 Interventional Studies
    • 6.4.2 Observational Studies
    • 6.4.3 Expanded Access Studies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 COVID-19 Clinical Trials Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global COVID-19 Clinical Trials market is categorized based on

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Interventional Studies
• Observational Studies
• Expanded Access Studies

By End User

• Hospitals
• Clinics
• Research Institutes
• Others

By Trial Type

• Drug Trials
• Vaccine Trials
• Diagnostic Trials
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Moderna, Inc.
• AstraZeneca PLC
• Johnson & Johnson
• BioNTech SE
• Novavax, Inc.
• Sanofi S.A.
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Roche Holding AG
• GlaxoSmithKline PLC
• Regeneron Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.